Hexa Reports Market Research Reports and Insightful Company Profiles
Enbrel (etanercept) (Rheumatoid Arthritis) Global Share and Size, Growth and Overview, Forecast and Market Analysis to 2023
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.
Browse Detail Report With TOC @ http://www.hexareports.com/report/enbrel-etanerceptrheumatoid-arthritis-forecast-and-market-analysis-to-2023/details
Amgen's Enbrel (etanercept) is a soluble TNF inhibitor used for the treatment of moderate-to-severe active RA patients who are unresponsive to one or more csDMARDs. Enbrel is a leading biologic agent and is approved for multiple immunological indications, including psoriasis and ankylosing spondylitis. It is a fusion protein made by recombinant DNA technology, where the TNF receptor is combined with the Fc portion of human immunoglobulin G1 (IgG1). Enbrel binds to and neutralizes both lymphotoxin and TNFa, thus preventing synovial inflammation (DrugBank, 2012; Scott, 2012).
Hexa Reports Market Research Reports and Insightful Company Profiles Scope - Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Enbrel (Etanercept) including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Enbrel (Etanercept) for the top 10 countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China and India. Reasons To Buy - Understand and capitalize by identifying products that are most likely to ensure a robust return. - Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential. - Make more informed business decisions from insightful and in-depth analysis of Enbrel (Etanercept) performance. - Obtain sales forecast for Enbrel (Etanercept) from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India). Request A Sample copy of This Report @ http://www.hexareports.com/sample/42253
Table of Contents Table of Contents 6 1.1 List of Tables 8 1.2 List of Figures 9 2 Introduction 10 2.1 Catalyst 10 2.2 Related Reports 11 2.3 Upcoming Related Reports 14 3 Disease Overview 15 3.1 Etiology and Pathophysiology 15 3.1.1 Etiology 15 3.1.2 Pathophysiology 15 3.2 Symptoms 20 3.3 Prognosis 21 3.4 Quality of Life 21
Hexa Reports Market Research Reports and Insightful Company Profiles 4 Disease Management 22 4.1 Diagnosis and Treatment Overview 22 4.1.1 Diagnosis 22 4.1.2 Treatment Guidelines 24 4.1.3 Leading Prescribed Drugs for the Treatment of RA 33 4.1.4 Clinical Practice 34 5 Competitive Assessment 40 5.1 Overview 40 6 Enbrel (etanercept) 42 6.1 Overview 42 6.2 Efficacy 44 6.3 Safety 45 6.4 SWOT Analysis 46 6.5 Forecast 47 7 Appendix 48 7.1 Bibliography 48 7.2 Abbreviations 52 7.3 Methodology 55 7.4 Forecasting Methodology 55 7.4.1 Diagnosed RA Patients 55 7.4.2 Percentage of Drug-Treated Patients 56 7.4.3 General Pricing Assumptions 56 7.4.4 Individual Drug Assumptions 57 7.4.5 Generic and Biosimilar Erosion 58 7.5 Primary Research - KOLs Interviewed for This Report 59 7.6 Primary Research - Prescriber Survey 61 7.7 About the Authors 62 7.7.1 Analyst 62 7.7.2 Reviewer 62 7.7.3 Therapy Area Director 63 7.7.4 Global Head of Healthcare 63 7.8 About GlobalData 64 7.9 Disclaimer 64
Browse Full Report @ http://www.hexareports.com/report/enbrel-etanercept-rheumatoid-arthritisforecast-and-market-analysis-to-2023/details
Hexa Reports Market Research Reports and Insightful Company Profiles About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States Phone Number 1-800-489-3075 Email Us: sales@hexareports.com Our Website: http://www.hexareports.com/ Visit Our Blogs: http://hexareports.blogspot.in